Control group (standard hospital treatment) + Group Hydroxychloroquine + Group Hydroxychloroquine and apixaban + Group Apixaban
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Complication
Conditions
Complication
Trial Timeline
Jul 1, 2020 → Dec 23, 2020
NCT ID
NCT04788355About Control group (standard hospital treatment) + Group Hydroxychloroquine + Group Hydroxychloroquine and apixaban + Group Apixaban
Control group (standard hospital treatment) + Group Hydroxychloroquine + Group Hydroxychloroquine and apixaban + Group Apixaban is a phase 3 stage product being developed by Pfizer for Complication. The current trial status is completed. This product is registered under clinical trial identifier NCT04788355. Target conditions include Complication.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04788355 | Phase 3 | Completed |
Competing Products
20 competing products in Complication
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Fospropofol + Propofol/Lidocaine | Eisai | Approved | 85 |
| exenatide | Eli Lilly | Phase 2 | 52 |
| Metformin + Placebo | Eli Lilly | Approved | 85 |
| LOKELMA 5 GM Powder for Oral Suspension + Placebos | AstraZeneca | Approved | 85 |
| deep neuromuscular block | Merck | Pre-clinical | 23 |
| Sugammadex + Neostigmine/Glycopyrrolate | Merck | Approved | 85 |
| Quadravalent human papillomavirus vaccine | Merck | Approved | 85 |
| Sugammadex + Neostigmine | Merck | Approved | 85 |
| Sugammadex 100 MG/ML [Bridion] | Merck | Approved | 85 |
| Letermovir 480 mg once daily | Merck | Phase 3 | 77 |
| Rocuronium | Merck | Pre-clinical | 23 |
| Everolimus + Tacrolimus + Mycophenolic acid | Novartis | Approved | 85 |
| Ranibizumab + 0.9% Sodium Chloride | Novartis | Phase 2/3 | 65 |
| Aztreonam Lysine for Inhalation (AZLI) | Gilead Sciences | Approved | 84 |
| Liraglutide + Placebo | Novo Nordisk | Approved | 84 |
| Semaglutide Treatment + Sitagliptin 100mg | Novo Nordisk | Approved | 84 |
| Donepezil | Pfizer | Approved | 84 |
| sodium thiosulfate | Sanofi | Pre-clinical | 22 |
| Finerenone Oral Tablet + Placebo | Bayer | Phase 2 | 49 |
| LA-EP2006 + Neulasta® | Sandoz Group | Phase 3 | 74 |